SOBI slips after Ionis lowers Tryngolza sales forecast
10/11/2026 10:31
BUZZ-SOBI slips after Ionis lowers Tryngolza sales forecast ** Shares in Swedish biopharmaceutical company SOBI SOBIV.ST slip around 2%
** Pareto Securities analyst Filip Wiberg attributes the move to Monday's Ionis report
** Ionis IONS.O cut 2026 sales forecast for its severe hypertriglyceridemia drug Tryngolza to $50 million from a previous range of $100-$110 million
** Wiberg adds Tryngolza is seen as quite a significant growth driver for SOBI from 2027 and beyond
** DB cuts its rating on the stock to "hold" from "buy", citing the Ionis move on Tryngolza
** It says the Tryngolza launch weakness is a negative in an otherwise "solid" picture with business growing strong double digits, it says
(Reporting by Marta Frackowiak)
Recent news on Swedish Orphan Biovitrum AB (publ)
See all newsTop of the Street: SOBI, Sonova, BAT, Imperial Brands
SOBI slips after Ionis lowers Tryngolza sales forecast
Brief: Swedish Orphan Biovitrum Executive Sells, Buys Shares
Europe Research Roundup: Centrica, Fuchs, URW
Brief: Swedish Orphan Biovitrum Proposes Börje Ekholm As New Chair And Board Member At 2027 AGM